tbuckley/cabot-search huggingface dataset:
Interaction of Both SH2 Domains of SHP-2 with a PD-1 Homodimer Is Required for PD-1-Mediated Inhibition of T Cell Responses
Authors: Nikolaos Patsoukis, Asia Council, Anders Berg, Kankana Bardhan, Jessica D Weaver, Kathleen M. Mahoney, Gordon J. Freeman, Vassiliki A. Boussiotis
Journal: Blood (2016)
Impact of EGFR tyrosine kinase inhibitors on skeletal-related events in EGFR mutation-positive non-small cell lung cancer patients with bone metastases.
Authors: Tatsuya Yoshida, Kiyotaka Yoh, Koichi Goto, Shigeki Umemura, Seiji Niho, Hironobu Ohmatsu, Kanji Nagai, Yuichiro Ohe
Journal: Journal of Clinical Oncology (2012)

e18054 Background: Clinical outcome of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients with bone metastases is less well known. The purpose of this study was to evaluate the clinical outcome of EGFR mutation-positive NSCLC patients with bone metastases who were treated with EGFR tyrosine kinase inhibitors (TKIs). Methods: From January 2008 to December 2010, 127 patients received first-line chemotherapy for advanced or postoperative recurrent NSCLC with bone metastasis at our institution. EGFR mutational status was analyzed using a PCR-based assay for EGFR exons 18 to 21. Clinical outcome including the incidence of skeletal-related events (SREs), time to the first SREs from first-line chemotherapy and overall survival (OS) was evaluated by the EGFR TKIs-sensitive mutations status (either exon 19 deletion or L858R in exon 21). SREs were defined as a pathologic fracture, spinal cord compression, surgery to bone, radiation therapy (RT) to bone, other radiological intervention, and hypercalcemia of malignancy. Results: Sixty-two (50%) of the 125 patients were sensitive EGFR mutations positive. 39 of 62 (63%) EGFR mutation-positive patients were treated with EGFR TKIs (gefitinib or erlotinib) as first-line chemotherapy, and most of negative patients received cytotoxic agents such as platinum-based chemotherapy. Zoledronic acid were administered in 50 % of EGFR mutation-positive patients, and in 57 % of negative patients, respectively (P= 0.59). With a median follow-up of 13 months, the incidence of SREs were 21% in EGFR mutation-positive patients, and 38% in negative patients, respectively (P&lt;0.05). Additionally, median time to first SREs from first-line chemotherapy in EGFR mutation-positive patients was significantly longer than negative patients (13 months versus 6 months, P&lt;0.05). Median OS in mutation-positive patients was 26 months, as opposed to 12 months in negative patients (P&lt;0.05). Conclusions: Our study indicated that EGFR mutation-positive NSCLC patients with bone metastases who were treated with EGFR TKIs have favorable clinical outcome on SREs compared with mutation-negative patients.
Evaluation of circulating biomarkers of bone metastasis in early-stage breast cancer.
Authors: Windy Marie Dean-Colomb, Kenneth R. Hess, Elliana J. Young, Terrie Gornet, Beverly Carol Handy, Stacy L. Moulder, Nuhad K. Ibrahim, Lajos Pusztai, Daniel J. Booser, Vicente Valero, Gabriel N. Hortobagyi, Francisco J. Esteva
Journal: Journal of Clinical Oncology (2012)

10613 Background: Bone is the preferred site for metastasis of breast cancer, affecting approximately 70% of women with advanced disease. N-terminal of procollagen type 1 (P1NP), c-terminal peptide crosslinks (CTX), Osteocalcin (OC) and interleukin-6 (IL-6) are markers of bone turnover that may have clinical utility as predictors of breast cancer recurrence in the bone. Methods: Serum was collected from 168 patients with stage I/II/III breast cancer prior to treatment from 09/2001 to 12/2008 and stored at -80 C. Serum levels of P1NP, CTX, OC and IL-6 were determined using the Roche’s Elecsys 2010 automated immunoassay system. Correlations of biomarker levels with time to bone metastasis (BM) development were assessed with Cox proportional hazards regression analysis and the Kaplan-Meier method. Results: Among the 168 patients analyzed, 60 patients subsequently developed BM. The biomarkers all had skewed distributions with long right tails and thus were all analyzed on the log scale. Residual analysis suggested non-linear relationships between each biomarker and risk of developing BM during follow-up. Thus, we fit Cox proportional hazards regression models for each biomarker with quadratic polynomials (on the log scale). On univariate analysis, these analyses generated p = 0.33 for IL-6, 0.26 for osteocalcin, 0.40 for CTX, and 0.032 for P1NP. Adjusting for clinical factors (stage, age, race, post menopausal, ER/PR status, HER2 status, nuclear grade) yielded p = 0.0035 for the quadratic polynomial for log P1NP. A cut-point of 75 ng/mL identified patients with a short time to development of BM. The 1, 3, and 5-year freedom-from-BM probabilities were 96%, 77% and 66% for the 150 patients with P1NP values ≤ 75 ng/mL and 88%, 45%, and 36% for the 16 patients with P1NP values &gt; 75 ng/mL. The hazard ratio comparing patients with P1NP values ≤ 75 ng/mL to patients with P1NP values &gt; 75 ng/mL was 3.0 (95% CI, 1.5 - 6.2) and p = 0.0075 ng/mL. After adjustment for clinical factors, the hazard ratio was 3.4 (1.5, 7.6) with p = 0.0026. Conclusions: Serum P1NP levels &gt;75 ng/mL correlate with a shorter time to development of BM in patients with stage I-III breast cancer.
Skin Barrier Impairment during Early Infancy Precedes Sensitization to Respiratory Allergens at 5 Years of Age
Authors: Margaretha A. Faber, Deirdre M. Murray, Alan D. Irvine, Claire O'Halloran, Darina Sheehan, Didier G. Ebo, Jonathan O. Hourihane
Journal: Journal of Allergy and Clinical Immunology (2017)
Use of Proteomic and Flow Cytometry Assays to Characterize Innate Anti-Viral Immune Responses Using Cord Blood in a Birth Cohort Study
Authors: Jamee R. Castillo, Amanda Barlow, Amy Dresen, Brent F. Olson, Tamara A. Koepel, Iris A. Reyes, Jennifer Meece, Michael D. Evans, Casper G. Bendixsen, Matthew C. Keifer, James E. Gern, Christine M. Seroogy
Journal: Journal of Allergy and Clinical Immunology (2017)
Cytogenetic and molecular study of the PRDX4 gene in a t(X; 18)(p22; q23) translocation.
Authors: Heidrun D. Gerr, Michele Nassin, Yanming Zhang, Janet D. Rowley
Journal: Cancer Research (2005)

Proc Amer Assoc Cancer Res, Volume 46, 2005

138 

The AML1/RUNX gene on human chromosome 21q22 is often disrupted by translocations in leukemia of which more than ten have been cloned. Recently, we cloned a translocation breakpoint involving the AML1 gene and the PRDX4 gene on Xp22 in a leukemia patient with a t(X;21). PRDX4 is a member of the peroxiredoxin gene family which is involved in antioxidation. To determine whether the PRDX4 gene was involved in other translocations in patients with leukemia, we screened cells from 15 patients with leukemia and Xp22 abnormalities using the FISH (Fluorescence in situ hybridization) technique and a labeled BAC (Bacterial Artificial Chromosome) clone covering the PRDX4 gene. A split FISH signal was detected in one of the patients implicating PRDX4 involvement. This patient who had a Pro B cell ALL showed a t(X;18)(p22;q23) translocation on cytogenetic analysis as well as other cytogenetic abnormalities. A 22Mb area on chromosome 18 was investigated with 30 BAC clones to localize the translocation breakpoint and to define the partner gene on chromosome 18. The potential breakpoint could be narrowed to a 50 kilobase region between the genes SOCS6 and CBLN2. Two BAC clones (RP11-139B13, RP11-432G11) were found that showed a split signal on both the derivative chromosomes 18 and X and thus appeared to span the translocation breakpoint. Using two color FISH with the BAC for PRDX4 and one BAC on chromosome 18 that split, we saw a fusion signal on the X chromosome; the PRDX4 BAC translocated to an as yet unidentified small chromosome not chromosome 18, indicating a complex rearrangement. Some ESTs (Expressed Sequence Tags) but no known genes are located in the breakpoint region on chromosome 18. Molecular studies are in progress to clone the genomic breakpoint and to confirm the fusion gene. PRDX4 is the only gene implicated in antioxidation that has been involved in leukemia-associated translocations. This is the second example of its involvement in a translocation. We conclude that antioxidant enzymes might play a heretofore unrecognized role in leukemogenesis.
Long-term survival after distant metastasis in oropharyngeal carcinoma.
Authors: Sean M McBride, Paul M. Busse, John Ross Clark, Ron J. Parambi, Lori J. Wirth, Annie W Chan
Journal: Journal of Clinical Oncology (2012)

5594 Background: The possibility of cure after distant metastases (DM) in oropharyngeal carcinoma (OPC) is uncertain. We conducted a retrospective cohort study to determine outcome and factors predictive of survival after metastasis in patients with OPC. Methods: From 2003-2010, 24 patients definitively treated (96% with concurrent chemo-radiation) at the Massachusetts General Hospital for OPC subsequently developed DM. At initial diagnosis, HPV status was available in 13 patients, 12 of whom were positive; six patients had T4 and 12 N2c-3 disease. Imaging studies pertinent to the diagnosis of DM were re-reviewed; 83% of patients had DM pathologically confirmed. Overall survival (OS) was defined from 1st radiographic evidence of DM to either death or last follow-up. Cox regression was used to evaluate factors predictive of OS after DM. Results: Median time to DM after initial treatment was 8.25 months (range, 1.6-24). Twenty (83%) patients had isolated distant failure; of these, 6 had limited (1 lesion or 2 adjacent lesions) single-organ disease. Eighteen (75%) had treatment after DM (83% had chemotherapy, 61% radiation, and 33% surgery). Median survival after distant metastasis was 19.2 months. Median follow-up for survivors was 23.5 months (range, 7.9-60.3). In multivariate analysis, limited single-organ disease (HR=0.14, p=0.01, 95% CI 0.031, 0.67) was predictive of improved survival after DM; T4 disease at initial diagnosis predicted for decreased OS after DM (HR=3.9, p=0.01, 95% CI 1.31, 11.89). For patients with limited single-organ disease, the 2-year OS was 82% compared to 32% with extensive metastases (p = 0.006). Of the 6 patients with limited, single-organ metastatic disease, two remained alive at 59.4 and 60.5 months without evidence of disease; both had HPV-positive tumors. One patient had a solitary hepatic failure and received neoadjuvant chemotherapy followed by partial hepatectomy; the other had a solitary lung metastasis and received wedge resection followed by radiation. Conclusions: Limited, single-organ metastatic disease predicts improved survival after DM in OPC. Cure is possible in this group. Patients with limited, single-organ distant disease should be considered for aggressive, local salvage treatment.
Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse
Authors: Christopher B. Benton, Marina Konopleva, Rima M Saliba, Elizabeth J. Shpall, Stefan O. Ciurea, Partow Kebriaei, Amin M. Alousi, Uday R. Popat, Paolo Anderlini, Yago Nieto, Simrit Parmar, Zhihong Zeng, Julianne J Chen, Gabriela Rondon, Becky McMullin, Rui-Yu Wang, Hongbo Lu, Wendy D. Schober, Glenda G Woodworth, Alison Gulbis, Rita Cool, Wei Qiao, Peter F Thall, Michael Andreeff, Richard E. Champlin
Journal: Blood (2012)
A Randomized, Controlled Two-Center Pilot Trial of a 6-Month Exercise Training Program to Treat the Post-Thrombotic Syndrome: The EXPO Pilot Trial.
Authors: Susan Kahn, Ian Shrier, Stan Shapiro, Adrielle H Houweling, Andrew Hirsch, Robert Reid, Clive Kearon, Marc Rodger, Michael J. Kovacs, David Anderson, Philip S Wells
Journal: Blood (2009)
Erythroid Response (ER) Rates in Myelodysplastic Syndromes (MDS) Patients Treated with Epoetin Alfa (EPO) or Darbepoetin Alfa (DARB) Using International Working Group Response Criteria (IWGc): Comparative Meta-Analysis.
Authors: Suneel Mundle, Patrick Lefebvre, Mei S. Duh, Ahmed Bourezak, Behin Yektashenas, Victor Moyo
Journal: Blood (2006)
Photodynamic therapy for cervical intraepitherial neoplasia
Authors: S. Yamaguchi, H. Tsuda, M. Takemori, S. Nakata, S. Nishimura, N. Kawamura, R. Nishimura
Journal: Journal of Clinical Oncology (2004)

5031 Background: Photodynamic therapy (PDT) is a novel strategy for cervical intraepitherial neoplasia (CIN) that does not effect the surrounding normal tissues due to its tumor selectivity. In this study, we assessed the efficacy and toxicity of PDT for CIN. Methods: Between May 1996 and May 2003, 86 women with a histologic diagnosis of CIN (74: primary CINIII, 4: primary CINII, 8: abnormal cytology after conization of microinvasive carcinoma) were treated by PDT. A 2 mg/kg dose of porfimer sodium (Photofrin II) was administered intravenously at 48 to 60 hours prior to laser therapy. Treatment was performed with irradiation of 100 J/cm2 using an Exicimer Dye Laser (EDL) or a YAG-OPO Laser via a colposcope with an optical path for the laser. For the endocervix, a specially designed intracervical probe was used. After treatment, all patients were hospitalized in a dark room with protection from light. The primary effect of PDT was evaluated 3 months after treatment by colposcopy, cytology, and histologic examination. In 57 patients, HPV typing was performed using a PCR non-radioactive HPV detection system with the HPV L1 open reading frame consensus primers before and after treatment. Outpatient follow-up was done every 2 to 3 months after PDT. Results: The median age of all patients was 30 years (range: 19 to 49 years). A complete response (CR) was eventually achieved in all patients. Within 24 hours of laser treatment, necrosis of the CIN region occurred and atypical cells disappeared. In 53 out of 57 patients (93%), HPV was detected and high-risk HPV (16 +18) was detected in 22 patients before treatment. HPV could not be detected in 74% of HPV-positive patients after treatment. Toxicity was predominantly mild cutaneous photosensitivity (grade 1–2 in 28 patients and grade 3–4 in 1 patient). At present, the median follow-up period is 24.4 months (range: 2.2 to 79.5 months). In three patients, recurrence of CINIII occurred at 23.9, 30.1, 34.6 months after treatment, and they all required surgical management. Conclusions: PDT is not only an effective procedure for CIN, but also for HPV infection. No significant financial relationships to disclose.
Treatment for intestinal helminth infection [7] (multiple letters)
Authors: E. Michael, A. Bhargava, D. Bundy, R. Peto, E. Cooper, L. Savioli, M. Neira, M. Albonico, M. J. Beach, H. M. Chwaya, D. W. T. Crompton, J. Dunne, J. P. Ehrenberg, T. Gyorkos, J. Kvalsvig, M. G. Taylor, C. Urbani, F. Zheng, P. Garner, R. Dickson, C. Demellweek, P. Williamson, S. Awasthi
Journal: BMJ (2000)
Cytogenetic Evolution in Patients with IPSS Low and Intermediate-1 Risk. Study from the Spanish Group of Myelodysplastic Syndrome
Authors: Brayan Marcel Merchán, Margarita Ortega, María José Llamas-Poyato, Montserrat Cortés, Montserrat Arnan, Carlos Cerveró, Julia Montoro, Teresa Gimenez, María López, Leonor Arenillas, David Valcárcel
Journal: Blood (2014)
Multicolor Flowcytometry Analysis of Hematopoietic Stem and Progenitor Cells Subsets Among Basal and Mobilized Peripheral CD34+ Cells
Authors: Valentina Giai, Elona Saraci, Eleonora Marzanati, Christian Scharenberg, Monica De Stefanis, Paola Omedè, Eva Hellstrom-Lindberg, Antonio Palumbo, Benedetto Bruno, Mario Boccadoro, Dario Ferrero
Journal: Blood (2014)
Relationship between Quality of Response to Bortezomib (btz) and Clinical Benefit in Multiple Myeloma (MM) in the APEX and SUMMIT Studies.
Authors: Ruben Niesvizky, P.G. Richardson, P. Sonneveld, M.W. Schuster, M. Coleman, D. Irwin, E.A. Stadtmauer, T. Facon, J. Harousseau, A. Boral, K.C. Anderson
Journal: Blood (2006)
Serum Ferritin and Cardiac/Liver Magnetic Resonance Imaging In Evaluating Iron Overload for Patients with Bone Marrow Failure Conditions Undergoing Non-Myeloablative HSCT
Authors: Victoria J Tindell, Victoria T Potter, Rachel Kesse-Adu, Laura Reiff-Zall, Aloysius Y Ho, Ghulam J. Mufti, Antonio Pagliuca, Judith C. W. Marsh, ZiYi Lim
Journal: Blood (2010)
Determinants of adherence to physical activity guidelines among overweight and obese African American breast cancer survivors: Implications for intervention approach.
Authors: Selina Smith, Wonsuk Yoo, Benjamin E. Ansa, Steven S. Coughlin, Mary S. Whitehead
Journal: Journal of Clinical Oncology (2016)

178 Background: Public health agencies encourage breast cancer survivors (BCSs) to follow their physical activity guidelines (PAGs). However, adherence to these guidelines is low. African American (AA) BCSs are more often overweight or obese and less likely than women of other races to report adherence to physical activity (PA) recommendations. To address the research question, “what prevents AA BCSs from following PAGs,” we examined socioeconomic, clinical, and psychosocial correlates with PA levels. Methods: AA women diagnosed and treated for breast cancer participating in a breast cancer support group (n = 191) completed a lifestyle assessment tool (LAT) capturing demographic characteristics; breast cancer diagnosis and treatment history; health-related quality of life (HR-QoL); weight history, including body mass index and post-diagnosis weight gain; and physical activity. Logistic regression and analysis of variance were used to determine whether these covariates were associated with meeting ( &gt; 17.5 MET h/wk); partially meeting (8.75-17.5 MET h/wk); or not meeting ( &lt; 8.75 MET h/wk) PAGs. Results: Preliminary results indicate that 44.44% of AA BCSs met PAGs. This percent is below the national average for AA women (56.5%) and white women (67.5%). Conclusions: Identifying factors that influence adherence to physical activity behaviors is important in developing effective interventions. These findings may help generate hypotheses for future research to undergird efforts to increase PA among AA BCSs.
Effect of a soluble activin receptor type IIB on androgen-deprivation-induced effects on body composition
Authors: J. Lachey, A. Koncarevic, J. Ucran, R. S. Pearsall, M. L. Sherman, J. Seehra
Journal: Journal of Clinical Oncology (2009)

5133 Background: Androgen deprivation therapy (ADT) is a well-established treatment for hormone sensitive prostate cancer, but is associated with adverse side effects including loss of bone and lean mass and increased adipose mass. Activin receptor type IIB (ActRIIB) signaling is necessary for the negative regulation of lean tissue mass and treatment with a non-signaling, decoy ActRIIB results in a robust increase in lean tissue mass. Methods: Similar to ADT patients, orchiectomized (ORX) mice lose bone and lean mass and gain fat mass. To determine the therapeutic potential of inhibiting ActRIIB signaling to reduce the negative effects associated with ADT, we treated sham-operated (SHAM) and orchiectomized (ORX) mice with RAP-031, a fusion protein comprised of a form of the extracellular domain of ActRIIB linked to a murine Fc. Mice received twice weekly injections for 10 weeks with either vehicle (VEH) or 10 mg/kg RAP-031 (RAP). NMR scanning was used to determine body composition and whole body DEXA scans were performed to determine bone mineral density (BMD). Results: ORX resulted in a 4.4% decrease in BMD, an 18% reduction in lean tissue and a 41.6% increase in adiposity compared to the VEH-SHAM cohort. Both RAP-031treated groups of mice had significantly increased BMD and lean tissue mass and decreased adipose mass compared to their respective VEH groups. However, BMD, lean tissue and adiposity were not significantly different between the VEH-SHAM and RAP-ORX groups. These data illustrate that RAP-031 treatment completely attenuates ORX-induced alterations in bone, lean and fat mass. Conclusions: These data support the hypothesis that treatment with a form of soluble ActRIIB can offset negative side effects of ADT and have significant therapeutic implications for the treatment of patients with prostate cancer. [Table: see text] [Table: see text]
Identification of AADACL1 As a Novel Regulator of Human Platelets Via Chemoproteomics
Authors: Stephen P. Holly, Jae Won Chang, Sherry Niessen, Yacine Boulaftali, Matthew C. Smith, Ryan M. Phillips, Justin L. Black, Raymond Piatt, Weiwei Li, Andrew S. Weyrich, Wolfgang Bergmeier, Benjamin F. Cravatt, Leslie V. Parise
Journal: Blood (2012)
The expression and clinical significance of PD-L1 in patients with upper tract urothelial carcinoma.
Authors: Xinan Sheng, Zhisong He, Yan Kong, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Li Li Mao, Xuan Wang, Bin Lian, Xieqiao Yan, Si Ming Li, Jie Dai, Jun Guo
Journal: Journal of Clinical Oncology (2016)

444 Background: Primary upper tract urothelial carcinoma (UTUC) is rare. In China UTUCs are more common than in Western populations and account for 20–30% of all TCCs.An antibody that targets programmed death ligand-1 (PD-L1) pathway has been shown to be active towards various types of cancer including bladder urothelial carcinoma. In this study, we investigated the PD-L1 expression and prognostic significance in UTUC. Methods: Formalin-fixed paraffin-embedded tumor samples from 78 patients with upper tract urothelial carcinoma from Peking University Cancer Hospital and Peking Universiy First Hospital were retrieved. PD-L1 expression was evaluated by immunohistochemistry using rabbit monoclonal anti-PD-L1 antibody. PD-L1 positivity on tumor cell membrane was defined as ≥ 1% of tumor cell membrane staining.The clinical data of patients were retrospective collected. The multivariate analysis was used to assess the association of PD-L1 expressionwith tumor staging, pathological N classification, whether firstly diagnosed with metastasis, disease free survival(DFS) and overall survival (OS) in patients. Results: The positive rates of PD-L1 expression were 42.3% (33/78) for upper tract urothelial carcinoma. Sex,location, pathological tumor staging, pathological N classification, whether firstly diagnosed with metastasis did not correlate with PD-L1 expression. In patients with upper tract UC, PD-L1 expression was not associated with DFS and OS on univariate analyses. Conclusions: To our knowledge, this is first study about PD-L1 expression in UTUC patients. In this study, We found the PD-L1 expression in UTUC was higher than in the bladder urothelial carcinoma. It means anti-PD-L1 treatment may be better for advanced UTUC. There was no correlation between PD-L1 expression and outcome.
386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients
Authors: V.M. Patil, A. Joshi, V. Noronha, J. Deodhar, A. Bhattacharjee, S. Dhumal, C. Mv, A. Karpe, V. Talreja, A. Chandrasekharan, S. Turkar, K. Prabhash
Journal: Annals of Oncology (2016)
In Acute Promyelocytic Leukemia (APL) with Multiple Relapses Additional Prognostic Information Is Provided by FLT3 and Telomerase (hTERT) Quantitative Real-Time PCR.
Authors: Paolo Bernasconi, Silvia Calatroni, Barbara Rocca, Paola Maria Cavigliano, Carlo Castagnola, Marina Boni, Ilaria Giardini, Rita Zappatore, Jessica Quarna, Emilio Paolo Alessandrino, Cesare Astori, Mario Lazzarino
Journal: Blood (2004)